Advertise with us
Clinical Group

Journal of Clinical Research and Ophthalmology

ISSN: 2455-1414

DOI

CC By

Abstract Open Access
Editorial PTZAID: JCRO-2-111

Long-Term Outcome of Approved Pharmacotherapy for Diabetic Macular Edema: A Review of Randomized Controlled Trials in Fluocinolone Acetonide Implants, Dexamethasone Implants, Aflibercept and Ranibizumab

Fang-Ting Chen and Jia-Kang Wang*

Diabetic macular edema (DME) is a major sight-threatening cause in diabetic patients. The pathophysiology of macular edema involves both the presence of inflammation and angiogenic stimulant

regarding vascular endothelial growth factor (VEGF) [1]. Intravitreal injections of anti-VEGF, including ranibizumab [2-8], bevacizuamb [9], pegaptanib [10], aflibercept [11] are proven to be effective for managing DME. Intravitreal injections of corticosteroids, potent anti-inflammatory agents, such as fluocinolone acetonide implants (Retisert) [12], fluocinolone acetonide inserts (Iluvein) [13,14], dexamethasone implants [15,16], and triamcinolone acetonide [2] have been shown to be beneficial to DME. The Food and Drug Administration of US and European Medicines Agency have approved intravitreal injections of fluocinolone acetonide inserts (Iluvein), dexamethasone implants, aflibercept, and ranibizumab for treating DME. Herein the long-term outcome of the randomized controlled studies in these approved pharmacotherapies will be reviewed.

Published on: Feb 15, 2015 Pages: 15-18

Full Text PDF Full Text HTML DOI: 10.17352/2455-1414.000011

Advertisements

Peertechz @Social

Peertechz Tweets

Case Reports

Pinterest on JCRO